Carbonic anhydrase 13 (CA13)
Homo sapiens — UniProt Q8N1Q1
Data last refreshed: (UniProt release unknown)
Key facts
Carbonic anhydrase 13 (CA13) is a protein from Homo sapiens identified by UniProt accession Q8N1Q1, 262 residues long. MolForge cross-references it against 24 known binders and 30 disease associations.
- UniProt accession: Q8N1Q1; gene symbol CA13.
- Organism: Homo sapiens.
- Length: 262 amino acids.
- Approved drugs acting on it (DrugCentral): Ethoxzolamide.
- Top disease associations (Open Targets): epilepsy, neurodegenerative disease and carbonic anhydrase 13 measurement.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Carbonic anhydrase 13 |
|---|---|
| UniProt accession | Q8N1Q1 |
| Gene | CA13 |
| Organism | Homo sapiens |
| Length | 262 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (1)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (30)
Diseases linked to this target (Open Targets).
- epilepsy · score 0.44
- neurodegenerative disease · score 0.29
- carbonic anhydrase 13 measurement · score 0.21
- MODY · score 0.11
- type 2 diabetes mellitus · score 0.08
- obstructive sleep apnea · score 0.07
- type 1 diabetes mellitus · score 0.07
- diabetes mellitus, transient neonatal, 2 · score 0.07
- mean corpuscular volume · score 0.06
- hyperinsulinism due to glucokinase deficiency · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q8N1Q1-F1 | alphafold | PREDICTED | 96.76 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q8N1Q1.
Amino-acid sequence (262 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target CA13?
DrugCentral lists 1 approved drug whose mechanism of action is CA13: Ethoxzolamide.
Which diseases are associated with CA13?
The strongest Open Targets associations for CA13 are epilepsy, neurodegenerative disease, carbonic anhydrase 13 measurement, MODY and type 2 diabetes mellitus.
How long is the CA13 protein?
The Homo sapiens CA13 protein (UniProt Q8N1Q1) is 262 amino acids long.
Browse: Targets: C · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q8N1Q1 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q8N1Q1 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.